Suppr超能文献

类固醇受体测量质量控制的改进:对40000多例原发性乳腺癌的分布分析。法国组织与分子生物病理学研究小组

Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology.

作者信息

Romain S, Spyratos F, Goussard J, Formento J L, Magdelénat H

机构信息

Laboratoire d'Oncologie Biologique-Biopathologie Tissulaire, Faculté de Médecine Nord, Marseille, France.

出版信息

Breast Cancer Res Treat. 1996;41(2):131-9. doi: 10.1007/BF01807158.

Abstract

All French laboratories that routinely assay estradiol (ER) and progesterone (PR) receptors participate in the European EORTC quality control program based on twice-yearly analysis of 5 cytosolic preparations. This system has considerably reduced inter-laboratory variations, but does not cover all aspects of these assays. Analysis of receptor value distributions is also crucial to ensure that receptor measurements remain stable with time, independently of the laboratory and assay method. This study involved 83907 receptor assays carried out in the last 17 years by 17 laboratories belonging to the French Study Group on Tissue and Molecular Biopathology. The assays were based on radioligand binding (RLA) or immunoenzymology (EIA). For each laboratory, the medians and positivity rates were analysed according to two totally objective criteria, the patient's age and the year of assay, and according to histological grade and histological type of the tumor in order to verify the correlations classically described. Age-related distributions varied little between laboratories, compared with data published by 7 European EORTC laboratories [1]. The results remained relatively stable with time in the RLA method for ER and PR, and in the EIA method for PR. Median ER-EIA data showed a marked increase between 1987 and 1989, mainly due to changes in the quality of Abbott reagents during this period. Otherwise, this analysis confirms previous pathophysiological observations.

摘要

所有常规检测雌二醇(ER)和孕酮(PR)受体的法国实验室都参与了欧洲癌症研究与治疗组织(EORTC)的质量控制项目,该项目基于对5种胞质制剂的半年一次分析。这个系统大幅减少了实验室间的差异,但并未涵盖这些检测的所有方面。受体值分布的分析对于确保受体测量随时间保持稳定也至关重要,这与实验室和检测方法无关。本研究涉及法国组织与分子生物病理学研究组的17个实验室在过去17年中进行的83907次受体检测。这些检测基于放射性配体结合法(RLA)或免疫酶学法(EIA)。对于每个实验室,根据两个完全客观的标准分析中位数和阳性率,即患者年龄和检测年份,并根据肿瘤的组织学分级和组织学类型来验证经典描述的相关性。与7个欧洲EORTC实验室公布的数据相比,各实验室之间与年龄相关的分布差异不大[1]。在ER和PR的RLA方法以及PR的EIA方法中,结果随时间保持相对稳定。ER-EIA数据的中位数在1987年至1989年之间显著增加,主要是由于这一时期雅培试剂质量的变化。此外,该分析证实了先前的病理生理学观察结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验